Amplia uncovers new clue in pancreatic cancer drug trial

Amplia Therapeutics has advanced its cancer drug narmafotinib across four trials, with data suggesting it may work independently of common tumour-causing KRAS gene mutations.

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.